On January 6, 2026 BostonGene, the developer of the leading AI foundation model for tumor and immune biology, reported a strategic collaboration with AstraZeneca, a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, to advance oncology drug development using BostonGene’s multimodal AI platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration leverages BostonGene’s foundation model for tumor and immune biology to deliver predictive insights on patient-level safety and efficacy outcomes in early clinical trials. AstraZeneca will apply BostonGene’s omnimodal analytics to accelerate development timelines and reducing risk across its oncology portfolio.

"BostonGene’s platform combines deep biological insights with advanced AI and this collaboration will empower us to predict which patients will benefit from treatment helping us design safer, more effective therapies from the start," said Jorge Reis-Filho, MD, PhD, Chief of AI for Science Innovation, Enterprise AI Unit, AstraZeneca. "At AstraZeneca, we are focused on leveraging the vast and unparalleled potential of AI to accelerate clinical development and the delivery of innovative medicines to patients."

The initiative marks another key milestone in the application of foundation models to real-world clinical development. BostonGene’s approach integrates pre-trained foundation models combined with advanced multi-modal data analytics, including cell-free RNA (cfRNA) and tumor microenvironment profiling, to predict response dynamics and tolerability across diverse patient populations, enabling more adaptive, biomarker-informed development.

"We’re honored to partner with AstraZeneca, a global leader in oncology innovation," said Andrew Feinberg, President and CEO at BostonGene. "This collaboration demonstrates the power of foundational biology and multi-modal molecular insights to reshape how we develop, de-risk, and deliver therapies to patients. It is a major step toward transforming drug development through AI."

BostonGene is actively deploying its foundation model alongside global biopharma partners to accelerate clinical programs across the oncology spectrum. By integrating these AI-driven insights into R&D pipelines, BostonGene is optimizing regulatory pathways and securing evidence for label expansion. This partnership with AstraZeneca underscores the transformative power of AI-powered profiling to transform oncology development at scale.

(Press release, BostonGene, JAN 6, 2026, View Source [SID1234661785])

On January 6, 2026 DEM BioPharma, Inc. (DEM Bio), a biopharmaceutical company dedicated to discovering novel targets for solid tumors and developing innovative, first-in-class, cancer medicines, reported that preclinical data for DEM301, a first-in-class bifunctional antibody drug conjugate (ADC), will be presented at the 2026 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO GI), taking place January 8-10, 2026, in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

DEM301 targets a novel plasma membrane-associated glycoprotein protein, DEM-TXX, that is overexpressed in colorectal cancer and several other gastrointestinal malignancies. DEM-TXX plays roles in cell adhesion and myeloid cell suppression, and its expression is negatively correlated with disease progression, underscoring its potential significance in tumor biology.

"This ASCO (Free ASCO Whitepaper) GI presentation represents an important milestone for DEM BioPharma as we introduce DEM301 and its underlying biology to the oncology community for the first time," said Nenad Grmusa, CEO of DEM Bio. "DEM-TXX emerged from our scientific founders’ functional genomics screen and validated by DEM BioPharma as a target that appears to contribute to immune suppression in GI cancers. DEM301 was purpose-built to translate that biology into a differentiated ADC designed with a dual mechanism of action to directly kill tumor cells while engaging immune-mediated mechanisms."

DEM301 is a first-in-class bifunctional antibody drug conjugate composed of an afucosylated monoclonal antibody directed against DEM-TXX and conjugated to a clinically validated linker-payload. The molecule is designed to selectively target tumor cells expressing DEM-TXX while leveraging both direct cytotoxic delivery and immune-mediated mechanisms of action.

The preclinical data to be presented at ASCO (Free ASCO Whitepaper) GI will highlight potent and durable single-agent anti-tumor efficacy in preclinical models of colorectal and other GI tumors and a favorable safety profile in a humanized DEM-TXX mouse model, supporting advancement toward clinical development. DEM Bio is currently advancing DEM301 through preclinical pharmacology and toxicology studies and has initiated CMC process development and manufacturing development in preparation for a planned Phase 1a/1b clinical trial expected to begin in the second half of 2026.

ASCO GI Poster Presentation Details

Title: DEM301, a novel anti-DEM-TXX antibody-drug conjugate with potent anti-tumor activity for the treatment of gastrointestinal tumors
Session: Poster Session C: Cancers of the Colon, Rectum, and Anus
Abstract Number: 159; available on the ASCO (Free ASCO Whitepaper) GI website
Date & Time: January 10, 2026, 7:00 – 7:55 AM PST
Presenter: Sarah Carden, PhD, DEM BioPharma

(Press release, DEM BioPharma, JAN 6, 2026, View Source [SID1234661784])

On January 6, 2026 Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, reported that Immunome management reported it will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.

(Press release, Immunome, JAN 6, 2026, View Source [SID1234661783])

On January 6, 2026 ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company discovering and developing novel drugs to reprogram the immune response to cancer, reported that company representatives will attend and participate in one-on-one meetings at the 44th annual JP Morgan Healthcare Conference from January 12 to 15, 2026 in San Francisco, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the conference, CEO and Co-Founder Dr. Salim Dhanji will meet with investors to highlight how ME Therapeutics is reprogramming myeloid cells in the tumour microenvironment to directly target cancer cells as well as overcome suppression to restore T cell activity and enable a more effective anti-tumour response. ME Therapeutics will share progress on its therapeutic mRNA, in vivo CAR, and antibody programs and share development plans for the year ahead.

(Press release, ME Therapeutics, JAN 6, 2026, View Source [SID1234661782])

On January 6, 2026 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, reported that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 3:45 p.m. PT (6:45 p.m. ET) in San Francisco, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 30 days following the event.

(Press release, Nuvation Bio, JAN 6, 2026, View Source [SID1234661780])